Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Spacepharma R&D Israel Ltd |
| Country | Israel |
| Start Date | Aug 01, 2024 |
| End Date | Jul 31, 2026 |
| Duration | 729 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101189238 |
Over 2,000 R&D experiments have been done in Space until now.
Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments.
The low-gravity accelerates the development and preclinical testing of complex molecules e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patients lives and improving their QoL.To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space.
MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher.
For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.
Spacepharma R&D Israel Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant